Axel Bengtsson

Papers

Total Citations

H-Index

About

Axel Bengtsson is a leading figure in the development of organoid-based platforms for precision oncology, with a primary focus on pancreatic ductal adenocarcinoma—one of the deadliest and most treatment-resistant cancers. His landmark 2021 paper, *Organoid technology for personalized pancreatic cancer therapy*, has already garnered 30 citations, underscoring its influence in reshaping preclinical cancer modeling. Bengtsson’s major contribution lies in engineering patient-derived organoids that faithfully recapitulate tumor biology, enabling high-throughput drug screening and individualized therapeutic predictions. This work directly addresses the stagnant survival rates and poor drug responses that have long plagued pancreatic cancer care. By bridging the gap between bench and bedside, Bengtsson’s organoid systems offer a powerful tool to identify effective treatments for each patient’s unique tumor profile. His research not only advances our mechanistic understanding of pancreatic cancer but also paves the way for more efficient, personalized clinical trials. For students and researchers, Bengtsson’s work exemplifies how innovative tissue engineering can transform cancer research into actionable, patient-specific therapies.